DMS 114细胞

DMS114/DMS114细胞系/DMS114细胞株/DMS114小细胞肺癌细胞

Cell line name DMS 114

Synonyms DMS-114; DMS114; Darmouth Medical School 114

Accession CVCL_1174

Resource Identification Initiative To cite this cell line use: DMS 114 (RRID:CVCL_1174)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: FGFR genetic alteration cell panel (ATCC TCP-1034).

Part of: JFCR39 cancer cell line panel.

Part of: KuDOS 95 cell line panel.

Population: Caucasian.

Doubling time: 3.8 days (PubMed=6266631); 1.6 days (PubMed=2986244); 27 hours (PubMed=7718330).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Deep exome analysis.

Omics: Deep proteome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Caution: Originally classified as originating from a lung small cell carcinoma, but is reclassified as a thoracic SMARCA4-deficient undifferentiated tumor based on a number of criteria (PubMed=38180245).

Derived from site: In situ; Lung; UBERON=UBERON_0002048.

PubMed=7718330; DOI=10.1016/0959-8049(94)00472-H

Baguley B.C., Marshall E.S., Whittaker J.R., Dotchin M.C., Nixon J., McCrystal M.R., Finlay G.J., Matthews J.H.L., Holdaway K.M., van Zijl P.L.

Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer.

Eur. J. Cancer 31A:230-237(1995)

 

PubMed=9212023; DOI=10.1016/S0360-3016(97)00245-9

Krarup M., Poulsen H.S., Spang-Thomsen M.

Cellular radiosensitivity of small-cell lung cancer cell lines.

Int. J. Radiat. Oncol. Biol. Phys. 38:191-196(1997)

 

PubMed=9744504; DOI=10.1038/bjc.1998.553; PMCID=PMC2063065

Damstrup L., Voldborg B.G.R., Spang-Thomsen M., Brunner N., Poulsen H.S.

In vitro invasion of small-cell lung cancer cell lines correlates with expression of epidermal growth factor receptor.

Br. J. Cancer 78:631-640(1998)

 

PubMed=12712436; DOI=10.1002/ijc.11106

Hansen L.T., Lundin C., Spang-Thomsen M., Petersen L.N., Helleday T.

The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer.

Int. J. Cancer 105:472-479(2003)

 

PubMed=15900046; DOI=10.1093/jnci/dji133

Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y., Yamazaki K., Hamada J.-i., Tada M., Moriuchi T., Ishikawa Y., Kato Y., Tomoda H., Yamori T., Tsuruo T.

p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target.

J. Natl. Cancer Inst. 97:765-777(2005)

 

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

 

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

 

PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017

Kong D.-X., Yamori T.

JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.

Bioorg. Med. Chem. 20:1947-1951(2012)